drugset / Trial / NCT02380573

Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease

NCT02380573

RandomizedSingle-groupQuadruple-blindTreatment

Summary

A double-blind, placebo-controlled study that aims to investigate the effect of 2-week and 12-week administration of USP methylene blue (MB) on cerebral blood flow, functional connectivity, memory and attention cognitive abilities using fMRI and behavioral measures in healthy aging, mild cognitive impairment (MCI) and mild Alzheimer's disease (AD) subjects.

Timeline

Start
2015-07
Primary completion
2022-04-21
Completion
2023-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylene Blue Diagnostic / imaging agent 282 mg Oral
Background Phenazopyridine Small molecule 97.5 mg Oral